HER-2 Positive Breast Cancer Latest Advances

Find the Latest Research About HER-2 Positive Breast Cancer

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 690 publications

Plain language summary about how patients with HER2 positive breast cancer across Europe feel about their cancer, treatment, and future health and related implications for their treatment journey.

Plain language summary about how patients with HER2 positive breast cancer across Europe feel about their cancer, treatment, and future health and related implications for their treatment journey.

Journal: Future oncology (London, England)

Published: May 13, 2026

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

Journal: BMJ (Clinical research ed.)

Published: March 16, 2026

A Retrospective Interventional Study Examining Whether Successful Replacement Therapy After a Confirmed Vitamin D Deficiency Correlates with Improved Disease-Free Survival in the Curative Intent Treatment of HER2+ Breast Cancer.

A Retrospective Interventional Study Examining Whether Successful Replacement Therapy After a Confirmed Vitamin D Deficiency Correlates with Improved Disease-Free Survival in the Curative Intent Treatment of HER2+ Breast Cancer.

Journal: Nutrients

Published: March 10, 2026

Management of HER2+ Breast Cancer with and without Brain Metastases in Saudi Arabia: Literature Insights and an Expert Survey of Current Practices.

Management of HER2+ Breast Cancer with and without Brain Metastases in Saudi Arabia: Literature Insights and an Expert Survey of Current Practices.

Journal: Breast cancer (Dove Medical Press)

Published: January 27, 2026

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update).

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update).

Journal: Current oncology (Toronto, Ont.)

Published: January 16, 2026

Nutritional, Anti-inflammatory, and in-silico inhibitory Studies of Trametes versicolor (L.) Lloyd and Flammulina velutipes (Curtis) on HER2 breast cancer protein.

Nutritional, Anti-inflammatory, and in-silico inhibitory Studies of Trametes versicolor (L.) Lloyd and Flammulina velutipes (Curtis) on HER2 breast cancer protein.

Journal: Biochemistry and biophysics reports

Published: December 24, 2025

Integrative In-silico, Network Pharmacology, Pharmacogenomics and In-vitro Evaluation of Fulvestrant-Loaded Zinc Oxide Nanoparticles Targeting HER2 Positive Breast Cancer.

Integrative In-silico, Network Pharmacology, Pharmacogenomics and In-vitro Evaluation of Fulvestrant-Loaded Zinc Oxide Nanoparticles Targeting HER2 Positive Breast Cancer.

Journal: Pharmaceutical research

Published: November 29, 2025

Predictors of pneumonitis in patients treated with systemic therapy and radiotherapy for localized triple negative or HER2 positive breast cancer.

Predictors of pneumonitis in patients treated with systemic therapy and radiotherapy for localized triple negative or HER2 positive breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: November 28, 2025

Dually Decorated Palmitate-Containing Lipid Nanoparticles for the Targeted Delivery of siRNAs against HER2 and Hsp27 in HER2+ Breast Cancer.

Dually Decorated Palmitate-Containing Lipid Nanoparticles for the Targeted Delivery of siRNAs against HER2 and Hsp27 in HER2+ Breast Cancer.

Journal: Journal of medicinal chemistry

Published: November 24, 2025

Computational Characterization of Nabilone-Induced Disruption of the CB2-HER2 Receptor Complex in HER2+ Breast Cancer.

Computational Characterization of Nabilone-Induced Disruption of the CB2-HER2 Receptor Complex in HER2+ Breast Cancer.

Journal: Bioinformatics and biology insights

Published: November 24, 2025

The Role of Raf Kinase Inhibitor Protein (RKIP) in HER2+ Breast Cancer Immune Evasion.

The Role of Raf Kinase Inhibitor Protein (RKIP) in HER2+ Breast Cancer Immune Evasion.

Journal: Cells

Published: November 14, 2025

T-DXd shows promise in neoadjuvant therapy for HER2+ breast cancer.

T-DXd shows promise in neoadjuvant therapy for HER2+ breast cancer.

Journal: Nature reviews. Clinical oncology

Published: November 10, 2025

Showing 1-12 of 690

Last Updated: 06/30/2026